GlaxoSmithKline Plc has announced a new R&D strategy that will focus on discovering drugs that modulate the immune system – a new frontier for cancer medicine – and one that also supports the company’s global vaccines business.
The strategy was announced on 25 July during a press briefing by Emma Walmsley, the chief executive, concurrent with the release of the company’s second-quarter results. Hal Barron, the company’s new chief scientific officer, was also on hand to explain some of the thinking behind the strategy.